ARCHIVES

Risk Assessment Key In Long-Term Treatment

This article is from The Cancer Letter archive.

Vol. 31 No. 8 | August 29, 2008

Download PDF Visit The Full Archive

Related Articles

Chemo Can Harm Liver, Affect Surgical Outcomes

May 26, 2006

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

In Brief: Melanoma Precursors Consensus Conference Planned, DRCC Board Raps Centers Budget Cut

May 20, 1983

NSABP Accrual Slow, But Auditing Called “Impressive”

January 20, 1995

Boston Meeting To Look At “IRBs At Crsswoad”

August 12, 1988

Rewritten Five Year Plan For Centers Is Greeted Warmly By NCAB Committee

April 27, 1990